Clovis Oncology Inc (NASDAQ:CLVS)
| 11.52 BATS BZX Real-Time Price As of 12:17pm ET |  -0.58 / -4.79%Today’s Change | 2.93 Today|||52-Week Range 32.05 | -35.86% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $527.3M |
Company Description
Clovis Oncology, Inc. is a commercial stage biotechnology company, which engages in the acquisition, development, and commercialization of cancer treatments in the United States, Europe, and other markets. Its product development programs target specific subsets of cancer, and simultaneously develop, with partners, diagnostic tools intended to direct a compound in development to the patients most likely to benefit from its use. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.
Contact Information
Clovis Oncology, Inc. 5500 Flatiron Parkway Boulder Colorado 80301 |
Employees
Shareholders
| Individual stakeholders | 8.07% |
| Other institutional | 60.49% |
| Mutual fund holders | 34.74% |
Top Executives
| There are no executives to display. |
